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The vertebrate heart arises from the fusion of bilateral regions of anterior mesoderm to form a linear heart tube. Recent studies in mouse and
chick have demonstrated that a second cardiac progenitor population, known as the anterior or secondary heart field, is progressively added to the
heart at the time of cardiac looping. While it is clear that this second field contributes to the myocardium, its precise boundaries, other lineages
derived from this population, and its contributions to the postnatal heart remain unclear. In this study, we used regulatory elements from the mouse
mef2c gene to direct the expression of Cre recombinase exclusively in the anterior heart field and its derivatives in transgenic mice. By crossing
these mice, termed mef2c-AHF-Cre, to Cre-dependent lacZ reporter mice, we generated a fate map of the embryonic, fetal, and postnatal heart.
These studies show that the endothelial and myocardial components of the outflow tract, right ventricle, and ventricular septum are derivatives of
mef2c-AHF-Cre expressing cells within the anterior heart field and its derivatives. These studies also show that the atria, epicardium, coronary
vessels, and the majority of outflow tract smooth muscle are not derived from this anterior heart field population. Furthermore, a transgene marker
specific for the anterior heart field is expressed in the common ventricular chamber in mef2c mutant mice, suggesting that the cardiac looping
defect in these mice is not due to a failure in anterior heart field addition to the heart. Finally, the Cre transgenic mice described here will be a
crucial tool for conditional gene inactivation exclusively in the anterior heart field and its derivatives.
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The mammalian heart initially arises from the fusion of
bilateral regions of anterior mesoderm known as the cardiac
crescent. During ventral folding and foregut invagination of the
mammalian embryo, the two halves of this bilaterally
symmetrical primary heart field meet at the midline to form a
linear heart tube. As development proceeds, this linear tube is
remodeled into a four chambered heart with the future atrial
myocardium looping dorsal and anterior to the developing
ventricles. Concurrently, the aorta and pulmonary artery arise
from septation of the common outflow tract (Brand, 2003;
Harvey, 2002).
Recent studies have demonstrated that the embryonic
outflow tract and right ventricle are not derived from the0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: brian.black@ucsf.edu (B.L. Black).primary heart field, but instead have their origins in a second
population of cells known as the secondary or anterior heart
field (Abu-Issa et al., 2004; Kelly and Buckingham, 2002;
Yutzey and Kirby, 2002). The cells that comprise the anterior
heart field reside in the splanchnic and pharyngeal mesoderm
and appear to be progressively added to the arterial pole of the
developing heart at the time of cardiac looping (Kelly et al.,
2001; Mjaatvedt et al., 2001; Waldo et al., 2001). The
identification of a second population of cardiogenic mesoderm
that gives rise to the right ventricle and outflow tract provides a
potential explanation for the observation that numerous genes
and transgenes exhibit expression that is restricted to the
outflow tract and right ventricle (Kelly and Buckingham, 2002;
Schwartz and Olson, 1999). In addition, mutations in several
key cardiac transcription factors, including mef2c, Isl1, Nkx2.5,
Hand2, and Foxh1, appear to selectively affect the develop-
ment of the right ventricle and outflow tract (Cai et al., 2003;
Lin et al., 1997; Lyons et al., 1995; Srivastava et al., 1997; von87 (2005) 134 – 145
www.e
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ventricular chamber, and the heart fails to undergo normal
looping morphogenesis. However, it remains unclear whether
addition of the anterior heart field occurs normally in these
mice, and whether the observed cardiac phenotypes result from
a defect in anterior heart field development.
While it is clear that the myocardium is derived from at least
two mesodermal progenitor populations, the precise boundaries
of the secondary/anterior heart field, the lineages derived from
this population, and its contribution to the postnatal heart
remain unclear. In the chick, fate mapping studies have
revealed that the splanchnic mesoderm proximal to the
developing outflow tract constitutes a secondary heart field
that will contribute to the elongating outflow tract myocardium
(Mjaatvedt et al., 2001; Waldo et al., 2001). Similarly, a
population of cells in transgenic mice expressing lacZ under
the control of Fgf10 regulatory elements resides in the
splanchnic and pharyngeal mesoderm before contributing to
the myocardium at the arterial pole (Kelly et al., 2001). Other
studies have suggested that the anterior heart field gives rise to
the embryonic right ventricle as well as the outflow tract
(Zaffran et al., 2004), or that the secondary/anterior heart field
may have an even broader developmental potential (Cai et al.,
2003; Laugwitz et al., 2005; Meilhac et al., 2004a). We have
recently identified a promoter and enhancer from the mouse
mef2c gene that is sufficient to direct expression exclusively to
the anterior heart field during embryonic development (Dodou
et al., 2004). This cis-acting regulatory module from mef2c
directs expression to the anterior heart field beginning at
cardiac crescent stage at 7.5 dpc, to the pharyngeal mesoderm
and the arterial pole at the linear heart tube stage, and to the
outflow tract and right ventricle during subsequent embryonic
development. The enhancer is never active in the left ventricle
or atria and is silent during adulthood (Dodou et al., 2004). The
expression domain directed by the mef2c anterior heart field
enhancer is likely a subfield of that described elsewhere as the
second heart lineage (Meilhac et al., 2004a) or a more spatially
restricted component of the Isl1 expression domain (Cai et al.,
2003).
In the present study, we examined the expression of mef2c-
AHF-lacZ, which expresses lacZ under the control of the
mef2c anterior heart field promoter and enhancer, in mef2c
knockout mice. We show that the common ventricular chamber
in mef2c knockout mice expresses mef2c-AHF-lacZ, suggest-
ing that this chamber is composed of derivatives from both the
primary and secondary heart fields. Interestingly, the mef2c-
AHF-lacZ transgene is only expressed on the dorsal side of the
common ventricular chamber, suggesting that these mice are
not defective in the addition of the anterior heart field to the
common ventricle, but rather in the patterning or looping of the
ventricular chamber. We have also generated transgenic mice
that express Cre exclusively within the anterior heart field and
its derivatives in the right ventricle and outflow tract using this
regulatory element from mef2c. We used these anterior heart
field-specific Cre transgenic mice, termed mef2c-AHF-Cre, to
generate a fate map of the embryonic, fetal, and postnatal heart.
By crossing mef2c-AHF-Cre mice to ROSA26R Cre-depen-dent lacZ reporter mice (Soriano, 1999), we show that the
outflow tract, right ventricle, and the ventricular septum are
marked by the activity of the mef2c-AHF-Cre transgene.
In addition, the studies presented here demonstrate that cells
marked by the mef2c-AHF-Cre transgene contribute to the
endocardium of the right ventricle. We also show that within
the outflow tract, the myocardium and endothelium are marked
by the mef2c-AHF-Cre transgene, whereas the smooth muscle
layer of the outflow tract is largely derived from neural crest
with some anterior heart field contribution near the pulmonary
trunk. These studies also demonstrate that the epicardium and
coronary vessels have an embryonic origin distinct from the
anterior heart field population marked by mef2c-AHF-Cre.
Thus, these studies provide a fate map of a highly restricted
subdivision within the secondary/anterior heart field in mice
and describe the first transgenic mouse line with Cre activity
restricted to the anterior heart field and its derivatives. These
mice will be a crucial tool for examining the genetic pathways
that control cardiac development by conditional gene inactiva-
tion exclusively in the anterior heart field and its derivatives in
the outflow tract and right ventricle.
Materials and methods
Generation of anterior heart field-specific Cre transgene and mice
The mef2c-AHF-Cre transgene was generated by excising the 3970 bp
mef2c anterior heart field enhancer and promoter as an XhoI fragment from
plasmid Mef2c-F6/Frag3, which has been described previously (Dodou et al.,
2004). This enhancer and promoter fragment was then cloned into a Cre
expression plasmid containing the Cre cDNA and the SV40 splice and polyA
signal sequence to create plasmid mef2c-AHF-Cre. The approximately 5.5 kb
mef2c-AHF-Cre transgene fragment was then purified as a NotI fragment and
injected into the male pronuclei of fertilized oocytes as described previously
(Dodou et al., 2003). Cre positive founder mice were identified by Southern
blot using a Cre-specific radiolabeled probe on genomic DNA isolated from tail
biopsies. Male Mef2c-AHF-Cre transgenic mice were crossed to female
ROSA26R Cre-dependent lacZ reporter mice (Soriano, 1999) to screen for
Cre recombinase activity. Wnt1-Cre mice have been described (Danielian et al.,
1998) and were used to fate map neural crest descendants in the outflow tract
(Jiang et al., 2000). Mef2c knockout mice were kindly provided by John
Schwarz (Albany), and have been described (Lin et al., 1997). Mef2c-AHF-
lacZ mice, containing the mef2c anterior heart field enhancer directing
expression of lacZ, have also been described previously as mef2c F6/Frag2-
lacZ (Dodou et al., 2004). Mouse and embryo genotyping was performed by
Southern blot using standard methods and probes specific for each allele. All
experiments using animals complied with federal and institutional guidelines
and were reviewed and approved by the UCSF Institutional Animal Care and
Use Committee.
Analysis of Cre expression and recombination
Transgenic male founders or transgenic male offspring of female founders
were crossed to female ROSA26R reporter mice (Soriano, 1999). Embryos
were collected at 10.5 dpc and stained with 5-bromo-4-chloro-3-indolyl h-d-
galactopyranoside (X-Gal) to detect h-galactosidase activity, as previously
described (Anderson et al., 2004). After establishing three transgenic lines that
exhibited robust anterior heart field-specific expression, embryos, embryonic
tissues collected at various time points, and neonatal tissues were X-gal stained.
For analysis of sections from embryos younger than 14.5 dpc, representative X-
gal stained embryos were prepared and stained as described previously
(Anderson et al., 2004) and counterstained with Neutral Fast Red for better
visualization of histology. Embryos older than 14.5 dpc and neonatal hearts
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embedded in OCT (Tissue Tek #4583) on dry ice. Frozen samples were then
sectioned on a cryostat (Leica) at a thickness of 10 Am and allowed to dry
overnight. Sections were fixed in 4% paraformaldehyde, rinsed in phosphate-
buffered saline, pH 7.4 (PBS), and stained in X-gal solution. After adequate
staining (6–16 h), sections were rinsed in PBS and counterstained in Neutral
Fast Red.
Immunohistochemistry and in situ hybridization
Immunohistochemical detection of h-galactosidase and PECAM-1 was
performed as described previously with minor modifications (De Val et al.,
2004). Briefly, mef2c-AHF-Cre Tg/0; ROSA26R lacZ/+ embryos were
collected at 10.5 dpc and fixed overnight in 4% paraformaldehyde in PBS,
transferred into increasingly concentrated sucrose solutions from 0 to 30% in
PBS, embedded in OCT on dry ice, and cryosectioned at a thickness of 14 Am.
Sections were then analyzed for h-galactosidase expression by immunohisto-
chemistry using rabbit anti-h-galactosidase (ICN) as primary antibody diluted 1
in 1000 in 3% normal goat serum. Primary antibody binding was detected using
Alexa Fluor 488 goat anti-rabbit secondary antibody (Molecular Probes) diluted
1 in 300 in 3% normal goat serum. The endothelial cell marker PECAM-1 was
detected using a rat anti-mouse PECAM-1 antibody (Pharmingen) diluted
1:300 in 3% normal goat serum, and the secondary antibody was Cy3-
conjugated goat anti-rat (Jackson Immunoresearch) diluted 1 in 300 in 3%
normal goat serum.
Whole mount in situ hybridization was performed as described previously
(Wilkinson and Nieto, 1993). Briefly, embryos were fixed overnight in 4%
paraformaldehyde and then washed twice with phosphate-buffered saline (PBS)
and dehydrated through a series of PBT (1 PBS + 0.1% Tween20)-methanol
washes. Embryos were then rehydrated through a reciprocal series of PBT-
methanol washes and were treated at room temperature with 10 Ag/ml
proteinase K for varied times depending on age as described (Wilkinson and
Nieto, 1993). After proteinase K treatment, embryos were rinsed with 2 mg/ml
glycine in PBT followed by two successive washes in PBT at room
temperature. Embryos were fixed in 4% paraformaldehyde and 0.2%
glutaraldehyde for 20 min at room temperature, rinsed three times in PBT,
and incubated in hybridization solution (50% formamide, 1% SDS, 5 SSC, 50
Ag/ml yeast tRNA, 50 Ag/ml heparin) for 16 h at 70-C.
For in situ hybridization on sections, embryos were fixed, embedded in
paraffin, sectioned, and dewaxed as described previously (De Val et al., 2004).
Sections were then digested for 8.5 min in 40 Ag/ml proteinase K, fixed in 4%
paraformaldehyde for 20 min, dehydrated through a series of ethanol washes,
and allowed to dry. 50 Al of hybridization solution was added to each slide, and
they were incubated at 70-C for 16 h. In situ hybridization was carried out with
digoxigenin-labeled antisense or sense RNA probes at 100 ng/ml (whole
mount) or 1 Ag/ml (sections) in hybridization buffer. Following hybridization,
embryos or slides were rinsed through a series of formamide and SSC washes
and treated with RNaseA as described previously (Verzi et al., 2002). Signal
was detected using an alkaline phosphatase-conjugated anti-digoxigenin
antibody and BM Purple alkaline phosphatase substrate (Roche Pharmaceu-
ticals). Following staining, slides were counterstained with Neutral Fast Red for
visualization of embryonic structures. The Isl1 in situ probe plasmid was
generously provided by S. Evans (UCSD) and has been described (Cai et al.,
2003). The Fgf10 antisense probe was kindly provided by P. T. Chuang (UCSF)
and has been described previously (Chuang et al., 2003).
Results
An anterior heart field-specific transgene is expressed in the
common ventricular chamber in mef2c null mice
Coincident with ventral turning of an E8.5 mouse embryo is
the rightward looping of the embryonic heart. Previous studies
have identified a number of genes necessary for cardiac looping
morphogenesis, including Isl1, Foxh1, Hand2, Nkx2.5, and
mef2c (Cai et al., 2003; Lin et al., 1997; Lyons et al., 1995;Srivastava et al., 1997; von Both et al., 2004).Mice lacking these
genes share a common phenotype: a generally hypoplastic heart
with a single, linear ventricular chamber and death at midgesta-
tion. Interestingly, these genes also share a common expression
pattern in the anterior heart field or in tissues derived from that
progenitor population (Cai et al., 2003; Edmondson et al., 1994;
Lints et al., 1993; Srivastava et al., 1995, 1997; von Both et al.,
2004). It has been suggested that the migration of cells from the
anterior heart field into the linear heart tube may direct looping
morphogenesis, and that a lack of anterior heart field contribu-
tion to the common ventricular chamber may be the cause of the
looping defect in these mutant mice (Yelbuz et al., 2002). It has
also been suggested that the common ventricular chamber in
these knockout mice lacks right ventricle identity, expressing
primarily left ventricular markers (McFadden et al., 2000;
Thomas et al., 1998).
To test whether markers of the anterior heart field are
expressed in the single common ventricular chamber in mef2c
mutant mice, we examined the expression of an anterior heart
field-specific lacZ transgene, mef2c-AHF-lacZ, in mef2c
knockout embryos (Fig. 1). Previous work has shown that
this transgene is expressed exclusively in the anterior heart
field and its descendants in the right ventricle and outflow
tract during development (Dodou et al., 2004). LacZ
expression in wild type and mef2c null animals appeared
identical from 7.75 dpc until 8.25 dpc (Fig. 1, compare panels
A, B to E, F). However, by 9.0 dpc, mef2c null animals began
to show abnormal cardiac morphology (Figs. 1G, H). At this
stage, anterior heart field marked cells were observed in the
right ventricle and outflow tract of wild-type mice (Figs. 1C,
D). Interestingly, mef2c-AHF-lacZ expression was also
detected in the common ventricular chamber of mef2c null
embryos (Figs. 1G, H). These results indicate that the mef2c-
AHF-lacZ anterior heart field marker is expressed in the
common ventricular chamber in mef2c mutants. In the
unlooped heart of these mutant mice, the anterior heart field
marked cells comprise the dorsal anterior region of the
common ventricular chamber (Figs. 1G, H). This result
suggests that the unlooped ventricle in mef2c mutants has
progenitor cells from the anterior heart field, which should
normally give rise to the right ventricle, even though this
common ventricle lacks markers of right ventricular identity
(McFadden et al., 2000). The expression of this anterior heart
field marker in the hearts of mef2c mutant embryos strongly
suggests that cells from the anterior heart field are added to the
ventricle in mef2c null mice and possibly other looping
mutants.
An anterior heart field-specific Cre transgene under the control
of regulatory elements from mef2c
Anterior heart field marker expression in the hearts of mef2c
mutant mice was unexpected and suggests that we do not have
a full appreciation for the contribution or role of the anterior
heart field in the developing mouse heart. Indeed, there are
several discrepancies regarding contribution of the secondary/
anterior heart field to the developing heart (Cai et al., 2003;
Fig. 1. The anterior heart field contributes to the common ventricular chamber inmef2c null embryos. Whole mount and sectioned embryos from wild-type (A–D) and
mef2c knockout (E–H) embryos containing the mef2c-AHF-lacZ transgene were assayed for h-galactosidase activity. (A, E) Frontal view of presomite embryos
collected at 7.75 dpc with h-galactosidase activity detected in themedial portion of the cardiac crescent, consistent with the anterior heart field expression. (B, F) Frontal
view of 6 somite embryos collected at 8.25 dpc and stained with X-gal. (C, G) Lateral view (right side) of 16 somite embryos collected at 9.0 dpc and stained with X-gal.
Notice that, in the mutant (G), the unlooped heart is stained in the dorsal portion of the common ventricular chamber, whereas staining in the wild-type embryo (C) is
restricted to the right side of the ventricle (bulbus cordis). (D, H) Transverse sections through 16 somite embryos. Staining in the knockout is observed in the outflow and
dorsal portion of the common ventricle (H). Arrowheads mark the dorsal anterior portion of the common ventricular chamber in mef2c mutant mice. LV, left ventricle;
NT, neural tube; OFT, outflow tract; PM, pharyngeal mesoderm; RV, right ventricle; VC, common ventricular chamber. Scale bar is equal to 100 Am.
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many questions remain regarding the boundaries of anterior
heart field-derived cell populations. In addition, the contribu-
tion of the secondary/anterior heart field to the postnatal heartFig. 2. Generation of an anterior heart field-specific Cre transgenic mouse line. (A)
heart field promoter and enhancer were subcloned upstream of the cDNA encoding C
resulting construct was used to generate transgenic mice. (B–D) Three different mef2
reporter mice, and embryos were collected at 10.0 dpc. Cre activity was readily appa
right ventricle (RV). No expression was observed in the atria. RA, right atrium.has yet to be determined in detail. To address these issues, we
used an anterior heart field-specific promoter and enhancer
from mef2c to direct expression of Cre recombinase in
transgenic mice (Fig. 2A). We crossed these mice, termedSchematic representation of the mef2c-AHF-Cre transgene. The mef2c anterior
re recombinase and the SV40 splice and polyadenylation signal sequence. The
c-AHF-Cre transgenic founders were crossed to ROSA26R Cre-dependent lacZ
rent in the pharyngeal mesoderm (arrowheads), outflow tract (OFT), and future
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1999) to determine the contribution of this population of cells
to the developing mouse heart. As shown here and in previous
work (Dodou et al., 2004), the mef2c anterior heart field
enhancer is specific to the population of cells that make up the
anterior heart field and its derivatives in the outflow tract and
right ventricle. Expression directed by the enhancer is tightly
restricted to these tissues and is never observed in the left
ventricle or atria (Dodou et al., 2004).
Mef2c-AHF-Cre positive transgenic founder mice were
screened by crossing to ROSA26R lacZ reporter mice, which
activate lacZ expression in a Cre-dependent manner (Soriano,
1999). We screened six mef2c-AHF-Cre founder lines that
were positive for the transgene by Southern blot. Among these,
four had a pattern of h-galactosidase activity consistent with
the anterior heart field and its derivatives, whereas the other
two lines had no detectable X-gal staining (not shown). In the
lacZ expressing lines, h-galactosidase activity was detected in
the right ventricle, outflow tract, and pharyngeal mesoderm at
10.0 dpc, consistent with an anterior heart field origin (Fig. 2).
Three mef2c-AHF-Cre transgenic lines were characterized in
detail for Cre expression (Figs. 2B–D), and one of these lines,
200A, was chosen for further analysis.Fig. 3. The mef2c-AHF-Cre fate map overlaps with the expression of anterior heart
AHF-Cre transgenic mice crossed to ROSA26R Cre-dependent lacZ reporter mice
derivatives. Cre activity directed by the mef2c-AHF-Cre transgene is first detectable
mef2c-AHF-Cre expresses Cre in the migrating cells of the anterior heart field (arrow
heart field markers Fgf10 (E) and Isl1 (F) as shown by in situ hybridization. Expres
arrowheads point to the anterior heart field stained cells in panels E and F. By 9.5 dpc
ventricle (RV) and outflow tract (OFT), as well as in the pharyngeal mesoderm (PM
left ventricle (LV). Cre expression overlaps the expression of Isl1 in the pharyngeal m
expression patterns between mef2c-AHF-Cre marked cells (D) and Isl1 expressing c
neural tube.The mef2c-AHF-Cre transgene is active at early cardiac
crescent stage and its expression overlaps with markers of
the secondary/anterior heart field
To verify that Cre activity in mef2c-AHF-Cre mice was
specifically marking the anterior heart field, we compared h-
galactosidase expression in mef2c-AHF-Cre Tg/0; ROSA26R
lacZ/+ embryos with the expression of Isl1 and Fgf10, which
are early markers of the secondary/anterior heart field in mice.
Fgf10 was the first anterior heart field marker described (Kelly
et al., 2001), while Isl1 is an essential gene required for
secondary heart field development (Cai et al., 2003) and has
been shown to directly activate mef2c transcription in the
anterior heart field (Dodou et al., 2004). h-galactosidase
activity was first observed in mef2c-AHF-Cre Tg/0; ROSA26R
lacZ/+ embryos in the cardiac crescent at 7.5 dpc (Fig. 3A). By
8.0 dpc, Cre activity was strongly apparent in the cardiac
crescent as ventral folding was occurring to bring the two
lateral fields of splanchnic mesoderm cells together in the
dorsal anterior domain characteristic of the anterior heart field
(Fig. 3B). This pattern of expression overlapped the expression
of Fgf10 and Isl1, which are expressed in the early anterior
heart field but are also expressed broadly outside this domainfield markers during early cardiac development. (A–D) Embryos from mef2c-
exhibit h-galactosidase activity exclusively in the anterior heart field and its
in the dorsomedial region of the cardiac crescent at 7.5 dpc (A). By 8.0 dpc (B),
head). Expression of Cre at 8.0 dpc overlaps with the expression of the anterior
sion of Fgf10 and Isl1 is considerably more broad than the anterior heart field;
(C), Cre activity directed by the Cre transgene is detectable throughout the right
) component of the branchial arches (BA) and in the outlet region of the future
esoderm (G). Transverse sections of embryos collected at 9.5 dpc show similar
ells (H) in the pharyngeal mesoderm (PM). al, allantois; DA, dorsal aorta; NT,
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specifically marks cells only within the anterior heart field and
is robustly active even at early stages in cardiac development.
Expression of h-galactosidase at 9.5 dpc strongly marked cells
within the anterior heart field and its derivatives, including the
pharyngeal mesoderm, outflow tract, and right ventricular
myocardium (Figs. 3C, D). Similar histological sections of
E9.5 embryos showed overlapping expression between mef2c-
AHF-Cre marked cells and Isl1 mRNA in the pharyngeal
mesoderm and in the dorsal wall of the pericardium (Figs. 3D,
H). Taken together, these results show that expression of Cre in
mef2c-AHF-Cre transgenic mice marks the anterior heart field.
Mef2c-AHF-Cre expressing cells and their descendants
contribute to the right ventricle, outflow tract, and ventricular
septum
While previous work has suggested that anterior heart field-
derived cells give rise to a number of cardiac tissues in the
embryo, none have examined the contribution to the fetal or
postnatal heart in detail. Furthermore, some discrepancies exist
regarding the boundaries of secondary/anterior heart field
contribution to the mature heart (Cai et al., 2003; Meilhac et
al., 2004a,b; Waldo et al., 2001; Zaffran et al., 2004). To define
the contribution of the mef2c-AHF-Cre anterior heart field
marked population to the developing and postnatal heart, we
crossed these mice to ROSA26R Cre-dependent lacZ reporter
mice to generate a fate map (Fig. 4). We compared the Cre-
dependent lacZ expression in these crosses to the expression of
lacZ directly under the control of the mef2c anterior heart field
enhancer using mef2c-AHF-lacZ transgenic mice (Dodou et
al., 2004). The goal of these comparisons was to identify
regions of the heart that were marked by the Cre-derived fate
map but that never showed direct lacZ expression in mef2c-
AHF-lacZ transgenic hearts. This would indicate regions of the
heart that had embryological origins derived from the mef2c-
AHF-Cre defined anterior heart field and its descendants. In
addition, we sought to identify regions of the heart that were
not marked by the mef2c-AHF-Cre fate map, which would
indicate regions of the heart that were not derived from the
mef2c-AHF-Cre expressing population.
At 9.5 dpc, the mef2c anterior heart field enhancer was
clearly active in the future right ventricle and outflow tract, as
well as in the pharyngeal mesoderm (Figs. 4A, I). However, no
activity was observed in the future left ventricle in mef2c-AHF-
lacZ transgenic embryos (Figs. 4A, I). The Cre-derived fate
map also marked the right ventricle, outflow tract, and
pharyngeal mesoderm at 9.5 dpc (Figs. 4E, M). h-galactosidase
activity in mef2c-AHF-Cre embryos was also observed in the
future left ventricle at this stage (Figs. 4E, M), indicating that
cells marked at an earlier time by the mef2c enhancer
contribute to the future left ventricle since the enhancer itself
is never active in the left ventricle (Figs. 4A, I). The mef2c
anterior heart field enhancer continued to be active in the
outflow tract and right ventricle at 12.0 dpc (Figs. 4B, J).
Again, the Cre-derived fate map also marked these regions and
additionally marked the developing ventricular septum andproximal regions of the left ventricle at this stage (Figs. 4F, N).
By comparison, the activity of the mef2c anterior heart field
enhancer itself, as indicated in mef2c-AHF-lacZ transgenic
animals, was restricted to the right ventricle and outflow tract
and did not cross the ventricular septum at this or any other
stage of development (Figs. 4B, J).
By 14.5 dpc, the once common outflow vessel has been
distinctly divided into the pulmonary artery and aorta, and by
this stage, the activity of the mef2c anterior heart field enhancer
itself was largely restricted to a region of the right ventricle
near the pulmonary trunk (Fig. 4C). There was also some weak,
residual h-galactosidase activity in right ventricular myocardi-
um near the ventricular chamber in mef2c-AHF-lacZ transgen-
ic hearts (Figs. 4C, K). By contrast, h-galactosidase expression
in mef2c-AHF-Cre; ROSA26R embryos was observed
throughout the right ventricle, ventricular septum, the left
ventricle proximal to the septum, and in both outflow vessels at
this stage (Figs. 4G, O). In mef2c-AHF-lacZ neonatal hearts,
h-galactosidase activity continued to be observed weakly in the
right ventricular wall especially near the pulmonary trunk
(Figs. 4D, L). In mef2c-AHF-Cre; ROSA26R transgenic mice,
h-galactosidase activity was observed throughout the right
ventricle, proximal aorta and pulmonary artery, and throughout
the ventricular septum, while essentially no expression was
observed in the atria or most of the left ventricle (Figs. 4H, P).
It is notable that no mef2c-AHF-Cre marked cells were
detected in the majority of the left ventricle or in the atria at
this or any other developmental stage (Figs. 4E–H, M–P).
Taken together, the data presented in Fig. 4 demonstrate that
the outflow tract and right ventricle are marked by the activity
of the mef2c-AHF-Cre transgene, and that the ventricular
septum and proximal portions of the left ventricle are derived
from mef2c-AHF-Cre expressing cells in the anterior heart field
and their descendants. These data also demonstrate that the
majority of the left ventricle and the atria are not derived from
mef2c-AHF-Cre expressing cells in the anterior heart field and
pharyngeal mesoderm. This suggests that the mef2c anterior
heart field expression domain represents a subpopulation of the
larger secondary heart field in the mouse, which is marked by
the Isl1-Cre fate map (Cai et al., 2003).
Right ventricular and outflow tract endothelial cells are
marked by the mef2c-AHF-Cre transgene
The endocardium is the endothelial cell lining of the heart
and plays an important role in heart function and in reciprocal
signaling with the myocardium (Brutsaert, 2003). Despite the
importance of the endocardium, its developmental origins
remain to be defined in detail. Previous studies have indicated
that some endocardial cells are derived from the secondary
heart field, although the extent of this contribution remains
unclear (Cai et al., 2003). In crosses of mef2c-AHF-Cre
transgenic mice with ROSA26R Cre-dependent reporter mice,
we observed that the endothelial cells of outflow tract and right
ventricle were positively marked by X-gal staining (Fig. 4M).
To examine mef2c-AHF-Cre directed lacZ expression in the
endothelium in greater detail, we also assayed h-galactosidase
Fig. 4. The right ventricle, outflow tract, and ventricular septum are composed of mef2c-AHF-Cre expressing derivatives. Hearts collected from either mef2c-AHF-
lacZ (A–D, I–L) or mef2c-AHF-Cre Tg/0; ROSA26R lacZ/+ mice (E–H, M–P) were stained for h-galactosidase activity with X-gal. In panels I–K and M–O,
whole embryos were stained with X-gal and then cut in transverse sections. In panels L and P, dissected hearts were cut in transverse sections and then X-gal stained.
At 9.5 dpc, mef2c-AHF-lacZ directed expression was detected in the right ventricle (RV), outflow tract (OFT), and the pharyngeal mesoderm (PM) of the branchial
arches (BA) (A, I). Mef2c-AHF-Cre Tg/0; ROSA26R lacZ/+ mice exhibited a similar pattern of expression in these tissues, but the expression was broader and
extended into the right-most portion of the left ventricle (LV) (E, M). X-gal staining was also detected in the endocardium (en) at this stage; no expression was
observed in the common atrial chamber (At) at this stage. Mef2c-AHF-Cre marked cells in hearts collected at 12.0 dpc (F, N) were present in the same domains as in
mef2c-AHF-lacZ hearts (B, J), but extended throughout the right ventricle, through the developing ventricular septum (asterisk), and into the left ventricle. Note the
lack of staining in the right and left atria (RA and LA, respectively) and the absence of staining in the epicardium. At 14.5 dpc, mef2c-AHF-lacZ expression was
more restricted and less intense (C, K), with no staining in the pulmonary artery or ventricular septum (asterisk). Mef2c-AHF-Cre fate mapped cells were evident in
the pulmonary artery (PA) as well as the right ventricle and the portion of the left ventricle proximal to the septum (G, O). No staining was observed in the atria. In
the postnatal heart from mef2c-AHF-lacZ mice (D, L), positive cells were primarily found only at the base of the pulmonary trunk and scattered within the right
ventricle and aorta. In mef2c-AHF-Cre hearts (H, P), positive cells were detected in the right ventricle, outflow vessels, and throughout the entire ventricular septum
(asterisk). The atria, the majority of the left ventricle, and the coronary vessels were not marked by the mef2c-AHF-Cre transgene. Red dashed lines demark the
position of the ventricular septum in panels A–H. Ao, aorta; DA, dorsal aorta; NT, neural tube. Scale bar equals 100 Am.
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galactosidase antibody (Fig. 5A). We compared h-galactosi-
dase expression to the expression of the endothelial cell markerPECAM (Fig. 5B), and observed that h-galactosidase protein
was co-expressed with PECAM in the right ventricle and
outflow tract at 10.5 dpc (Fig. 5C). Taken together, the results
Fig. 5. The right ventricular endocardium and the endothelium and myocardium
of the outflow tract are derived from mef2c-AHF-Cre progenitors, and the
smooth muscle of the outflow tract is largely neural crest-derived. (A)
Immunohistochemical detection of h-galactosidase (h-gal) protein in a
transverse section through the right ventricle (RV) and outflow tract (OFT)
of a representative mef2c-AHF-Cre Tg/0; ROSA26R lacZ/+ transgenic heart
collected at 10.5 dpc. (B) PECAM staining to detect endothelial cells in the
same section shown in panel A. (C) Merged image of panels A and B showing
overlap of h-galactosidase and PECAM in the endocardium (EC), but not in the
myocardium (Myo), which was only marked by h-galactosidase. (D) A
representative transverse section through the pulmonary artery of a mef2c-
AHF-Cre Tg/0; ROSA26R lacZ/+ transgenic embryo at 14.5 dpc. Cre activity
was evident in the myocardial (myo) and endothelial cell (EC) layers of the
outflow tract, while no activity was observed in the smooth muscle cell (SMC)
layer. (E) Section through the pulmonary artery of aWnt1-Cre Tg/0; ROSA26R
lacZ/+ embryo at 14.5 dpc. Cre activity was evident in the smooth muscle
layer, but not in endothelial cells or the myocardial layer of the outflow tract.
Representative parafrontal sections through the pulmonary artery (pulm. trunk)
at the junction with the right ventricle from a mef2c-AHF-Cre Tg/0; ROSA26R
lacZ/+ embryo (F) or a Wnt1-Cre Tg/0; ROSA26R lacZ/+ embryo (G) at 14.5
dpc. Mef2c-AHF-Cre marked cells were detected in the myocardial compo-
nents of the vessel, as well as in some of the cells subadjacent to the
endothelium, presumably smooth muscle, and in cells of the pulmonary valve
leaflets (asterisks). Wnt1-cre activity was detected in the smooth muscle cell
layer of the pulmonary artery and aorta, the leaflets of the pulmonary valves
(asterisks), and in the conotruncal (CT) septum. Scale bar is equal to 100 Am.
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proximal outflow tract and right ventricle are marked by the
mef2c-AHF-Cre transgene.
Epicardium, coronary vessels, and the majority of outflow tract
smooth muscle are not derived from mef2c-AHF-Cre
expressing cells in the anterior heart field
Our work presented here, as well as the work of others (Cai
et al., 2003; Kelly et al., 2001; Mjaatvedt et al., 2001; Waldoet al., 2001), demonstrates that anterior heart field-derived
cells contribute to the myocardial component of the outflow
vessels of the heart (Fig. 4). Interestingly, previous studies
have shown that the cardiac neural crest also contributes to the
outflow vessels, giving rise to the smooth muscle of the tunica
media (Epstein et al., 2000; Jiang et al., 2000; Waldo et al.,
1999). Very recently, a study performed in chick showed that
the smooth muscle of the most proximal outflow tract is
derived from secondary heart field rather than cardiac neural
crest (Waldo et al., 2005b). To address which cells of the
outflow vessels are derived from each specific developmental
field in the mouse, we compared ROSA26R directed h-
galactosidase expression in the outflow tract from transgenic
mice expressing mef2c-AHF-Cre and Wnt1-Cre (Danielian et
al., 1998). Wnt1-Cre marks all neural crest cells and their
descendants, including the cardiac neural crest and its
derivatives in the outflow tract (Danielian et al., 1998; Jiang
et al., 2000). Mef2c-AHF-Cre-derived cells comprised the
endothelial lining and outer myocardial component of the aorta
and pulmonary artery, but did not appear to contribute to the
smooth muscle cells in the more distal regions of the outflow
tract (Fig. 5D). Instead, neural crest-derived cells comprised
the smooth muscle layer within the more distal outflow tract
(Fig. 5E). Neural crest descendants were not observed within
the endothelial lining of the outflow tract or in the muscular
myocardial portion of the outflow vessels (Fig. 5E). Near the
base of the heart, both Wnt1-Cre and mef2c-AHF-Cre-derived
cells contributed to the smooth muscle cells of the pulmonary
trunk and to the cells of the pulmonary valve leaflets (Figs. 5F,
G). Thus, it appears that the cardiac neural crest and the
anterior heart field each give rise to smooth muscle cells of the
outflow tract near the base of the heart but have largely non-
overlapping contributions to the more distal regions of the
outflow vessels (Figs. 5D–G).
Previous studies have suggested that the coronary vessels
and epicardium have a common developmental origin in the
proepicardial organ (septum transversum) (Olivey et al., 2004).
We examined whether these tissues might also be derived in
part from the anterior heart field, particularly for the
epicardium and vessels overlying the right ventricle (Fig. 6).
Our results clearly show that the epicardium lying directly
adjacent to the positively marked right ventricular myocardium
was negative for h-galactosidase activity, indicating that the
epicardium is not derived from mef2c-AHF-Cre expressing
cells (Fig. 6A). Similar to the epicardium, whole mount
staining of neonatal hearts, or sections through coronary
vessels showed little or no investment of cells marked by the
mef2c-AHF-Cre transgene (Figs. 6B, C). Occasionally, mef2c-
AHF-Cre marked cells were observed within coronary vessels
(Fig. 6C) suggesting the possibility that some smooth muscle,
or possibly endothelial, cells of anterior heart field origin might
contribute or be added to the coronary vessels. Overall,
however, we conclude that the coronary vessels and the
epicardium have developmental origins that are largely distinct
from the anterior heart field population marked by mef2c-AHF-
Cre, which is consistent with a common developmental origin
for these structures and the addition of these cells after the
Fig. 6. The epicardium and coronary vessels are not derivatives of the anterior heart field. (A) Representative section from a mef2c-AHF-Cre Tg/0; ROSA26R lacZ/+
heart collected at 14.5 dpc shows strong h-galactosidase activity in the myocardium (Myo), and negative staining in the adjacent epicardium (Epi). The coronary
vessels of the neonatal heart were largely negative for h-galactosidase activity as seen in whole mount (B), or transverse sections (C). Notice also that the epicardium
of the neonatal heart is negative for h-galactosidase staining. EC, endothelial cells; LA, left atrium; PA, pulmonary artery; RA, right atrium; RV, right ventricle. Scale
bar is equal to 100 Am.
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2004).
Discussion
It has only recently become clear that the arterial portion of
the developing heart arises from a discrete population of cells
called the secondary or anterior heart field (Kelly et al., 2001;
Mjaatvedt et al., 2001; Waldo et al., 2001). Understanding the
developmental potential of this novel population of cells is
required for future studies focused on the role of the anterior
heart field in cardiac development and its involvement in
congenital heart disease. In the present study, we have
described a Cre transgenic mouse line, mef2c-AHF-Cre, which
exhibits activity that is tightly restricted spatially to a subset of
cells within the secondary/anterior heart field and its descen-
dants. We used these mice to follow the contribution of this
population of cells within the anterior heart field to the
embryonic and postnatal heart. These studies demonstrate that
the myocardium of the outflow tract and right ventricle is
marked by mef2c-AHF-Cre expression and that the ventricular
septum and proximal portions of the left ventricle are derived
from mef2c expressing cells within the anterior heart field. This
work also shows that the endocardium of the right ventricle and
proximal outflow vessels are marked by the mef2c-AHF-Cre
transgene, while the epicardium and coronary vessels do not
share a common origin with this population of anterior heart
field-derived cells. Importantly, we also show that this
population of cells within the anterior heart field does not
contribute to the majority of the left ventricle or the atria.
Previous studies have come to differing conclusions when
defining the boundaries of secondary/anterior heart field
contribution to the heart. Using retrospective fate mapping, a
clonal boundary was observed between the left and right
ventricles, with the ventricular septum arising from both right
and left ventricular myocyte clones, suggesting a dual origin
for the septum (Meilhac et al., 2004b). The mef2c-AHF-Cre
generated fate map described here spans this clonal boundary,
suggesting that the entire ventricular septum is derived from
this anterior heart field population of cells (Fig. 4). Indeed,more recent retrospective clonal analyses suggest that myocyte
clones can span the septal boundary and further suggested that
the outflow tract is derived exclusively from secondary heart
field, while the right ventricle and atria are derived from
progenitors from both the primary and secondary heart fields
(Meilhac et al., 2004a). Other recent work defines the
secondary heart field as Isl1 expressing progenitors that give
rise to the outflow tract and right ventricle, as well as the
majority of the cells in the left ventricle and developing atrium
(Cai et al., 2003). By contrast, the fate map generated by
mef2c-AHF-Cre described here has more restricted spatial
boundaries and does not include the atria or the majority of the
left ventricle. One possible explanation for this discrepancy is
that Isl1 is expressed in the precardiac mesoderm prior to the
partitioning of the primary and secondary heart fields, and
therefore Isl1 may mark descendants of both heart fields (Abu-
Issa et al., 2004; Meilhac et al., 2004a). Mef2c-AHF-Cre may
be activated in the precardiac mesoderm after the secondary
heart field has a distinct identity from the primary heart field
(Fig. 3) and, therefore, marks only the secondary/anterior heart
field. This notion is consistent with fate mapping studies done
in chick embryos where the secondary heart field appears to
contribute only to the arterial pole of the developing heart
(Mjaatvedt et al., 2001; Waldo et al., 2001). Alternatively, the
mef2c-AHF-Cre-derived fate map may represent a restricted
subdomain of the secondary heart field with the mef2c
enhancer marking only a portion of the larger Isl1 expression
domain, which is a notion that is also consistent with previous
studies (Cai et al., 2003; Meilhac et al., 2004a).
Genetic fate mapping has several advantages over other fate
mapping approaches, which rely on embryological manipula-
tions and ex vivo culture systems. A Cre-based, genetic fate
mapping approach, such as the one utilized here, provides
nearly exact spatial resolution and does not require any
perturbations to the developing embryo, thus allowing an
embryonic fate map to be extended into adulthood. The
disadvantage of the fate map presented here is that it does
not provide a strict temporal boundary from which to map the
fate of cells. By comparing the activity of the mef2c enhancer
driving lacZ expression directly to the enhancer generated fate
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exhibit enhancer activity at any time during development yet
were marked by the fate map. This allowed us to use mef2c-
AHF-Cre to identify the contribution of this population of cells
within the anterior heart field to the postnatal heart, and
importantly, to identify regions of the heart that lacked
contribution from anterior heart field cells marked by the
mef2c-AHF-Cre transgene. The use of multiple fate mapping
methods, including genetic and other approaches, is essential
for a detailed understanding of the developmental potential of
the secondary/anterior heart field, including the subpopulations
and expression domain gradients within this progenitor pool.
Anterior heart field contribution in mutant mice with defective
heart looping
Knockout studies in mice have shown that several cardiac
transcription factors are required for cardiac development.
Mice with mutations in mef2c, Hand2, Nkx2.5, Isl1, and Foxh1
exhibit defects in looping morphogenesis and have only a
single hypoplastic common ventricular chamber, and each of
these genes is strongly expressed in the anterior heart field (Cai
et al., 2003; Lin et al., 1997; Lyons et al., 1995; Srivastava et
al., 1997; von Both et al., 2004). It has been proposed that the
common ventricular chamber in mice with mutations in these
genes may lack right ventricular identity, which is consistent
with a failure of the anterior heart field to be added to the
developing heart (McFadden et al., 2000; Srivastava et al.,
1997). We examined the expression of a transgenic marker of
the anterior heart field, mef2c-AHF-lacZ, in mef2c knockout
embryos. Our results show that this marker of the anterior heart
field is expressed in the common ventricular chamber of mef2c
null embryos, suggesting that the looping defects seen in
mef2c, and possibly other mutant mice, are not due to failure of
anterior heart field migration into the ventricular chamber.
Interestingly, however, the mef2c-AHF-lacZ anterior heart field
marker is misexpressed in mef2c knockout embryos in a dorsal
rather than a right-sided pattern. These observations suggest
that the failure in looping morphogenesis in mef2c knockout
animals may be due to a failure of anterior heart field-derived
cells to properly differentiate, migrate in an appropriate pattern,
or communicate with adjacent tissues. A failure of anterior
heart field cells to differentiate properly is consistent with
previous observations of the Hand2 cardiac enhancer in mef2c
null mice, which suggested that the common ventricular
chamber lacked cells with right ventricular identity (McFadden
et al., 2000). Future studies will explore the role of the anterior
heart field in cardiac morphogenesis.
Interaction of the anterior heart field with the cardiac neural
crest and other tissues
The studies presented here have focused primarily on the
expression of a transgenic marker of the anterior heart field and
the embryological contributions of that population of cells to
the heart; however, it is clear that anterior heart field-derived
components of the heart do not function autonomously andmust integrate with several other lineages. We have described
that the epicardium and coronary vessels come from a
developmental origin distinct from the anterior heart field,
consistent with addition to the heart from the proepicardial
organ after addition of the anterior heart field (Kirby, 2002). It
will be interesting to determine how anterior heart field-derived
cardiomyocytes create a permissive environment for subse-
quent addition of these tissues to the heart. The data presented
here demonstrate that the majority of the left ventricle and the
atria are not derived from the regions of anterior heart field
marked by the activity of the mef2c-AHF-Cre transgene. It
remains to be determined how the primary and secondary heart
fields are merged and whether reciprocal interactions between
these two cardiogenic populations control boundary formation
between the ventricles.
The cardiac neural crest is required for proper outflow tract
development (Hutson and Kirby, 2003), and it has been shown
to contribute to the smooth muscle of the outflow vessels
(Epstein et al., 2000; Jiang et al., 2000; Waldo et al., 1999).
Before septation, the outflow tract is primarily a myocardial
tissue of secondary heart field origin. As the outflow tract
shortens, the myocardial component is reduced, potentially by
programmed cell death (Sugishita et al., 2004; Watanabe et al.,
1998) or by transdifferentiation of myocardium to smooth
muscle cells (Ya et al., 1998). Concurrent with outflow tract
shortening, cardiac neural crest cells migrate into the outflow
tract and contribute to the developing aorticopulmonary septum
as well as to the tunica media of the developing great vessels
(Jiang et al., 2000).
The smooth muscle cells of the outflow tract are positioned
between the anterior heart field-derived myocardial and
endocardial components of these vessels, and anterior heart
field progenitors in the pharyngeal mesoderm are juxtaposed
with neural crest-derived mesenchyme in the branchial arches.
The close proximity of these two lineages and their eventual
co-contribution to the outflow tract suggests the possibility of
an intricate reciprocal signaling relationship between the
secondary/anterior heart field and the cardiac neural crest.
Indeed, in animals lacking cardiac neural crest cells, secondary
heart field myocardium fails to be added properly to the arterial
pole of the embryonic heart (Waldo et al., 2005a; Yelbuz et al.,
2002). It will be interesting to determine if the neural crest also
requires signaling from the anterior heart field for proper
addition to the outflow tract and valves. The mef2c-AHF-Cre
transgenic mouse line will allow the ability to ablate genes
specifically in the anterior heart field and its derivatives, which
will permit a more detailed study of reciprocal signaling
interactions in the outflow tract.
Implications of an anterior heart field-specific Cre transgenic
mouse line
Several common congenital anomalies result from outflow
tract defects, including tetralogy of Fallot, double outlet right
ventricle, persistent truncus arteriosus, and transposition of the
great arteries (Srivastava, 2003; Winlaw et al., 2005). Because
the outflow tract is derived from at least two distinct
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crest, it will be important to define the role of each of these
lineages in congenital malformations.
Conditional gene inactivation is an integral approach to
understanding developmental processes such as cardiac devel-
opment. In order to understand the function of genes
specifically within the anterior heart field, lineage restricted
Cre mice must be developed. Currently, the only existing Cre
line described for this lineage is Isl1-Cre, which is expressed
broadly in the embryo, including the secondary heart field
(Srinivas et al., 2001). Isl1-Cre has the advantage of being
expressed earlier than the mef2c-AHF-Cre transgene described
here (Cai et al., 2003). Indeed, ISL1 binding is required for
mef2c anterior heart field enhancer activation (Dodou et al.,
2004). In addition, an inducible Isl1-Cre transgenic mouse has
been developed and has the advantage of temporal control of
Cre activity (Laugwitz et al., 2005). Furthermore, Isl1 is not
expressed in many of the anterior heart field-derived cells that
comprise the developing myocardium and outflow tract (Cai et
al., 2003). However, Isl1 is expressed in many developing
tissues and lineages outside of cardiac progenitor populations,
including motor neurons, oral epithelium, cranial sensory
ganglia, inner ear, thalamus, pituitary, pancreatic endothelium
and mesenchyme, and distal tubular cells of the kidney
(Ahlgren et al., 1997; Dong et al., 1991; Mitsiadis et al.,
2003; Nakagawa and O’Leary, 2001; Pfaff et al., 1996; Radde-
Gallwitz et al., 2004). Consistent with the broad expression of
Isl1, the Isl1-Cre transgene is also broadly expressed during
development and is clearly expressed outside cardiac progen-
itor populations. Indeed, the Isl1-Cre transgenic mouse line
was first utilized to mark cells of motor neurons and dorsal root
ganglia (Srinivas et al., 2001). In contrast, expression of the
mef2c-AHF-Cre transgene described in the present study is
highly restricted to the anterior heart field and its derivatives in
the developing heart, and this novel reagent will allow for
conditional inactivation of genes exclusively in the anterior
heart field and its derivatives. This will be particularly relevant
since many genes expressed in the anterior heart field are also
expressed in the primary heart field or in the neural crest, and
conditional inactivation approaches will be necessary to
determine specific functions of these genes in the anterior
heart field, right ventricle, and outflow tract independent of
other lineages. These types of studies and the use of multiple
distinct Cre lines will provide important insights into the
mechanisms underlying the congenital anomalies that appear to
impact the secondary/anterior heart field and its derivatives in
the outflow tract.
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